WO2013066838A1 - Composés et procédés - Google Patents

Composés et procédés Download PDF

Info

Publication number
WO2013066838A1
WO2013066838A1 PCT/US2012/062513 US2012062513W WO2013066838A1 WO 2013066838 A1 WO2013066838 A1 WO 2013066838A1 US 2012062513 W US2012062513 W US 2012062513W WO 2013066838 A1 WO2013066838 A1 WO 2013066838A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
heteroaryl
aryl
compound
group
Prior art date
Application number
PCT/US2012/062513
Other languages
English (en)
Inventor
Shomir Ghosh
Mercedes Lobera
Ryan Paul Trump
Cunyu Zhang
Original Assignee
Glaxosmithkline Llc
Tempero Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc, Tempero Pharmaceuticals, Inc. filed Critical Glaxosmithkline Llc
Publication of WO2013066838A1 publication Critical patent/WO2013066838A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to compounds that inhibit histone deacetylase
  • HDAC HDAC enzymes
  • preparation of these compounds the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity and pharmaceutical compositions comprising these compounds.
  • Chromatin organization involves DNA wound around histone octamers that form nucleosomes.
  • Core histones with N-terminal tails extending from compact nucleosomal core particles can be acetylated or deacetylated at epsilon lysine residues affecting histone-DNA and histone-non-histone protein interactions.
  • Histone deacetylases HDACs catalyze the deacetylation of histone and non-histone proteins and play an important role in epigenetic regulation.
  • HDAC1 HDAC1 , HDAC2, HDAC3, HDAC8 and HDAC1 1
  • HDAC4 HDAC5
  • HDAC6, HDAC7, HDAC9 and HDAC10 which shuttle between the nucleus and the cytoplasm
  • SIRT1-7 class III HDACs
  • Class II HDACs are further characterized as class lla HDACs and class lib HDACs.
  • HDAC9 is a class lla histone deacetylase highly expressed in human Tregs.
  • HDAC9 deficiency 1 ) increases Foxp3 expression (and other Treg markers), 2) increases Foxp3 and histone 3 acetylation, 3) increases Foxp3 DNA binding, 4) increases Treg numbers, 5) increases suppressive activity in vitro and in vivo, and 6) ameliorates murine colitis.
  • Tregs which are deficient in HDAC9 induce permanent tolerance of fully mismatched cardiac allografts.
  • HDAC9 inhibitors maybe useful for treatment of diseases and disorders associated with abnormal cell proliferation, differentiation and survival, e.g. breast and prostate tumors.
  • HDAC7 a class lla histone deacetylase
  • HDAC7 enhances Treg suppression in vitro and in vivo.
  • HDAC7 enhances FOXP3+ Treg function and induces long-term allograft survival.
  • HDAC6 inhibition in vivo decreased severity of colitis in the dextran sodium sulphate-induced colitis model and the
  • CD4 + CD62Lhigh adoptive transfer model of colitis In addition, inhibition of HDAC6 with a subtherapeutic dose of rapamycin led to prolonged cardiac allograft survival.
  • an orally available small molecule selective inhibitor of Class II HDAC activity (more specifically HDAC9 or HDAC7 or HDAC6) is expected to modulate autoimmune diseases through expansion and enhancement of Treg activity.
  • HDAC4 and 5 impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes and maybe potentially useful for the treatment of muscle and heart diseases including cardiac hypertrophy and heart failure. Also, inhibition of Class II HDAC activity, represents a novel approach for disrupting or intervening in cell cycle regulation.
  • HDAC9 is also highly expressed in human B cells. Relative to normal B cells, expression of HDAC9 is deregulated in cell lines derived from B cell tumors and HDAC9 is highly overexpressed in cells derived from patients with non-Hodgkin's lymphoma (http://icr.ac.uk/research/team leaders/Zelent Arthur/Zelent Arthur Rl/index.shtml). HDAC4 and HDAC9 have both been reported to be overexpressed in CD19+ cells from patients with Waldenstrom Macroglobulinemia (Sun et al., Clinical Lymphoma, Myeloma & Leukemia, 201 1 , p. 152)
  • Class Ma HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) have been reported to associate with Bcl-6, a transcription factor implicated in the pathogenesis of B-cell malignancies (Lemercier et al, Journal of Biological Chemistry, 2002, p. 22045, and Petrie et al, Journal of Biological Chemistry, 2003, p. 16059). Due to these interactions class lla HDACs have been suggested to modulate the transcriptional repression of BCL6 and participate in its role in B-cell activation and differentiation, inflammation, and cell-cycle regulation (Verdin et al. TRENDS in Genetics, 2003, p. 286) .
  • HDAC6 a class lib HDAC, has been reported to play an important role in aggresomal protein degradation, making it a target for the treatment of B cell
  • HDAC4 a small molecule selective inhibitor of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 and/or HDAC9 is expected to be beneficial in the treatment of B-cell malignancies by targeting one or several of the above enzymes
  • HDAC4 has been linked to a variety of neurodegenerative disorders: it is a downstream target of Parkin (associating it to Parkinson's disease); it is a major component of intranuclear inclusions produced in NIIND. HDAC4 also contains a conserved glutamine rich domain, such domain has been observed to increase susceptibility to amyloid formation associated with Alzheimer's disease (Majdzadeh et al. Front. Biosci., 2009, p. 1072). Heterozygotes of HDAC4 knockouts crossed to R6/2 mice (Huntington's disease model) led to improved motor/behavior and reduced aggregation
  • HDAC4 and HDAC5 localization are regulated by neuronal activity, and HDAC5 nuclear import is increased in diseased neurons of Huntington's disease patients.
  • HDAC7 has been implicated in regulating ataxin-7 turnover in a SCA-7 model (Mookerjee S et al., J Neurosci., 2009, p. 15134).
  • HDAC6 is expressed in most neurons and most abundantly in cerebellar Purkinje cells; the degeneration of this type of neurons is observed in patients with spinocerebellar ataxia type 1 (SCA1 ) or SCA7. HDAC6 is involved in regulating microtubule dynamics and protein degradation and a defect in microtubule-based transport may contribute to the neuronal toxicity observed in Huntington's disease (Kazantsev et al. Nature Reviews Drug Discovery, 2008, p. 854). Additionally, HDAC6 activity has been shown to be required for autophagic degradation of aggregated huntingtin, suggesting a role in protecting cells from polyQ toxicity (Iwata, et al., J. Biol. Chem., 2005, p. 40282).
  • HDAC4 or HDAC5 or HDAC6 or HDAC7or HDAC9 is expected to be beneficial in the treatment of neurodegenerative diseases.
  • Class II HDAC inhibitors have therapeutic potential in the study and/or treatment of the various diseases or conditions described herein.
  • HDAC inhibitors Many of the known small-molecule HDAC inhibitors, however, inhibit all HDAC isoforms. It would be advantageous to identify HDAC inhibitors that inhibited one or more, but not all HDAC isoforms.
  • the invention is directed to a compound according to Formula I:
  • f is 0 or 1 ;
  • each of the aryl, heteroaryl, cycloalkyl and heterocyclyl moieties of Z is optionally substituted by 1-3 substituents each independently selected from the group consisting of oxo, halogen, -(C C 6 )alkyl, halo(C C 6 )alkyl, (d-C 6 )alkoxy, halo(C C 6 )alkoxy, -NH 2 , hydroxyl, cyano, -NH((CrC 6 )alkyl), -N((C C 6 )alkyl)((Ci-C 6 )alkyl,), (C C 6 )alkylcarbonyl-,
  • each R 1 is independently selected from the group consisting of hydrogen
  • (C 3 -C 6 )cycloalkyl, heterocyclyl, aryl-(C 0 -C 6 )alkyl-, and heteroaryl-(C 0 -C 6 )alkyl-, is optionally substituted by 1 -3 R 2 substituents each independently selected from the group consisting of oxo, hydroxyl, cyano, -(CrC 6 )alkyl, -(CrC 6 )alkoxy, nitro, -amino((Ci-C 6 )alkyl),
  • Y is (C 2 -C 6 )alkyl (that is, a (C 2 -C 6 )alkylenyl moiety) or an optionally substituted aryl or heteroaryl, optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, -(CrC 6 )alkyl, halo(Ci-C 6 )alkyl, (CrC 6 )alkoxy, halo(C 1 -C 6 )alkoxy, amino, hydroxyl, cyano, -NH((C 1 -C 6 )alkyl),
  • d is 0 or 1 ;
  • e 0, 1 , 2, 3, 4, 5 or 6;
  • any of said optionally substituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, (d-C 6 )alkyl, halo(CrC 6 )alkyl, (CrC 6 )alkoxy,
  • heterocyclyl -C(Ph) 3 , aryl, heteroaryl, aryl(C 1 -C 6 )alkyl-, and heteroaryl(C 1 -C 6 )alkyl-;
  • a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, a method of inhibiting HDAC by contacting a HDAC with the compound of Formula I or a salt thereof, and a method of treating a subject having a disease or disorder mediated by inhibition of a HDAC comprising administering the compound of Formula I, or a salt thereof, or a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, to the subject.
  • the invention is further directed to a pharmaceutical composition comprising a compound of the invention.
  • the invention is still further directed to methods of inhibiting HDAC enzymes and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
  • alkyl represents a saturated, straight or branched hydrocarbon moiety.
  • exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl (or /-propyl), n-butyl, isobutyl, sec-butyl, f-butyl (or tert-butyl), n-pentyl, iso-pentyl (3-methyl-butyl), neo-pentyl (2,2-dimethylpropyl), etc.
  • (Ci-C 4 )alkyl refers to an alkyl containing from 1 to 4 carbon atoms.
  • any substituent term containing a "C 0 alkyl” moiety indicates that the substituent term excludes the presence of an alkyl moiety in that substituent.
  • the term "-(C 0 -C 6 )alkyl-SR 1 " is intended to describe both "-SR 1 " and “-(d-C 6 )alkyl-SR 1 " substituents.
  • alkyl When the term “alkyl” is used in combination with other substituent groups, such as “haloalkyl” or “cycloalkyl-alkyl” or “arylalkyl”, the term “alkyl” is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
  • arylalkyl is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH 2 -phenyl).
  • cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring.
  • (C 3 -C 8 )cycloalkyl refers to a non-aromatic cyclic
  • hydrocarbon ring having from three to eight ring carbon atoms.
  • (C 3 -C 8 )cycloalkyl groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Alkoxy refers to a group containing an alkyl radical attached through an oxygen linking atom.
  • (Ci-C 4 )alkoxy refers to a straight- or branched-chain
  • hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
  • exemplary "(CrC 4 )alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
  • Aryl represents a group or moiety comprising an aromatic, monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms and to which may be fused 1-3 cycloalkyl rings.
  • aryl is phenyl
  • Heterocyclic groups may be heteroaryl or heterocyclyl groups.
  • Heterocyclyl represents a group or moiety comprising a stable, non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocyclyl may be attached by any atom of the monocyclic or bicyclic radical which results in the creation of a stable structure. This term encompasses bicyclic heterocyclyl moieties where the rings are joined at two atoms per ring, as exemplified by the bonding arrangement in 2,5-diazabicyclo[2.2.1]heptyl,
  • octahydro-1 /-/-pyrrolo[3,2-6]pyridyl group octahydro-1 /-/-pyrrolo[3,2-6]pyridyl group.
  • This term specifically excludes bicyclic heterocyclyl moieties where the rings are joined at a single atom per ring (spiro), as exemplified by the bonding arrangement in a 1 -oxa-2-azaspiro[4.5]dec-2-en-3-yl group.
  • heterocyclyls include, but are not limited to, azetidinyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl,
  • heterocyclyl groups are
  • 5-membered and/or 6-membered heterocyclyl groups such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, dihydrofuryl, oxazolinyl, thiazolinyl or pyrazolinyl, piperidyl (or piperidinyl), piperazinyl, morpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxanyl, tetrahydro-2H-1 ,4-thiazinyl, 1 ,4-dioxanyl, 1 ,3-oxathianyl, and 1 ,3-dithianyl.
  • pyrrolidyl or pyrrolidinyl
  • tetrahydrofuryl or tetrahydrofuranyl
  • tetrahydrothienyl
  • Heteroaryl represents a group or moiety comprising an aromatic, monocyclic or bicyclic radical, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term also encompasses bicyclic heterocyclic-aryl compounds containing an aryl ring moiety fused to a heterocyclyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur where the nitrogen or sulfur heteroatoms are optionally oxidized.
  • heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (or furanyl), isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridyl (or pyridinyl), pyridyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazin
  • heteroaryl groups present in the compounds of this invention are 5-6 membered monocyclic heteroaryl groups.
  • Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
  • Selected 6-membered heteroaryl groups contain 1 , 2, 3 or 4 nitrogen ring heteroatoms.
  • Selected 5- or 6-membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and thiadiazolyl.
  • heteroaryl groups present in the compounds of this invention are 9-10 membered bicyclic heteroaryl groups.
  • Selected 9-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
  • Selected 10-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms.
  • Selected 9-10 membered heteroaryl groups include benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl,
  • alkyl, aryl, cycloalkyl, heteroaryl, etc. may be used to define a divalent substituent, such as a group bonded to two other groups. In this instance, such terms are intended to encompass divalent moieties.
  • pentyl may be used to represent a pentylenyl diradical -wherein the pentyl moiety is any one of a divalent straight (e.g. -CH 2 CH 2 CH 2 CH 2 CH 2 -) or branched (e.g. -CH 2 CH(CH 3 )CH 2 CH 2 -,
  • Haldroxy or “hydroxyl” is intended to mean the radical -OH.
  • the invention is directed to a compound according to Formula (l-a) and Formula (l-b):
  • f is 0 and the compounds have Formula (l-a). In another embodiment, f is 1 and the compounds have Formula (l-b). .
  • d is 0. In another embodiment, d is 1 .
  • e is 0. In another embodiment, e is 1. In further embodiment, e is 2. In a still further embodiment, e is 4.
  • d is 1
  • e is 1
  • f is 0.
  • Z is selected from the group consisting of hydrogen, halogen, -CF 3 , nitro, cyano,
  • any of said aryl or heteroaryl is optionally substituted by 1-3 substituents each independently selected from the group consisting of oxo, hydroxyl, cyano, -(C 1 -C 6 )alkyl, -(CrCe ⁇ lkoxy, nitro, -NR 1 R 1 , halogen, -SH, halo(C 1 -C 6 )alkyl and -(C 2 -C 4 )alkyl-NR 1 R 1 , wherein two R 1 groups, together with the nitrogen atom to which they are attached optionally form a heterocyclyl group.
  • Z is selected from the group consisting of hydrogen, -(C 0 -C 3 )alkoxy-(C 0 -C 3 )alkyl-aryl, -(C 0 -C 3 )alkoxy-(C 0 -C 3 )alkyl-heteroaryl, aryl,
  • Z is -(C 2 -C 4 )alkyl-NR 1 R 1 , and the two R 1 groups, together with the nitrogen atom to which they are attached, optionally form a heterocyclyl selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, and azetidinyl.
  • each R 1 is independently selected -H, -(d-C 6 )alkyl
  • -(Co-C 6 )alkyl-heteroaryl is optionally substituted by 1-3 substituents each independently selected from the group consisting of oxo, hydroxyl, cyano, -(CrC 6 )alkyl,
  • each R 1 is independently -(C 0 -C 6 )alkyl-aryl or
  • each R 2 is independently selected from the group consisting of -CH 3 , -F, -CI, -Br, -OH, -OCH 3 , -OCF 3 , -CF 3 , -NH 2, -NH((Ci-C 6 )alkyl), -N((C 1 -C 6 )alkyl)((C 1 -C 6 )alkyl), -(C 2 -C 4 )alkyl-N((C 1 -C 6 )alkyl), -(C 2 -C 4 )alkyl-N ((C 1 -C 6 )alkyl)((C 1 -C 6 )alkyl), and cyano.
  • R 1 is independently selected from the group consisting of phenyl, benzyl, methyl, ethyl, ferf-butyl and isopropyl.
  • Z is -H.
  • Y is (C 2 -C 6 )alkyl. In a further embodiment, Y is (C 2 -C 4 )alkyl.
  • Y is an optionally substituted phenyl or naphthyl, or a 5-6 membered or 9-10 membered heteroaryl, optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -(d-C 6 )alkyl,
  • Y is an optionally substituted phenyl, pyridyl or pyrimidinyl (more specifically, an optionally substituted phenyl or pyridyl), optionally substituted by 1 -3 substituents each
  • Y is unsubstituted phenyl, pyridyl or pyrimidinyl, specifically, Y is unsubstituted phenyl or pyridyl.
  • -S-(Ci-C 6 )alkyl-N(R 1 ) 2 -SO-(C C 6 )alkyl, -S0 2 -(C C 6 )alkyl, -(C 3 -C 6 )cycloalkyl, heterocyclyl, -C(Ph) 3 , aryl, heteroaryl, aryl(Ci-C 6 )alkyl-, and heteroaryl(Ci-C 6 )alkyl.
  • X is an optionally substituted phenyl, thienyl, pyridyl or indolyl, optionally substituted by 1 -3 substituents each independently selected from the group consisting of (Ci-C 6 )alkyl, halogen, hydroxyl, (Ci-C 6 )alkoxy, halo(CrC 6 )alkyl and halo(CrC 6 )alkoxy.
  • X is an optionally substituted phenyl, thienyl, pyridyl or indolyl (more specifically, phenyl or thienyl) group, optionally substituted by 1 or 2 substituents each independently selected from the group consisting of fluoro, hydroxy, and ferf-butoxy.
  • X is a 4-hydroxyphenyl group or an indolyl group, more specifically, X is a 4-hydroxyphenyl group.
  • the terms "compound(s) of the invention” or “compound(s) of this invention” mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a
  • any physical form thereof e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
  • non-solid forms e.g., liquid or semi-solid forms
  • solid forms e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)
  • mixtures of various forms e.g., including hydrate forms (e.g., mono-, di- and hemi- hydrates)
  • optionally substituted means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and groups or rings substituted by 1 -3 specified substituents.
  • the compounds according to Formula I may contain 1 -3 asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
  • Chiral centers such as chiral carbon atoms, may also be present in a substituent such as an alkyl group.
  • the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
  • compounds according to Formula I containing 1-3 chiral centers may be used as racemic mixtures, scalemic mixtures, or as diaseteromerically or enantiomerically pure materials.
  • Individual stereoisomers of a compound according to Formula I which contain 1-3 asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • polymorphism i.e. the capacity to occur in different crystalline forms. These different crystalline forms are typically known as "polymorphs.” It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
  • Formula I are preferably pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse,
  • salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention.
  • a salt may be readily prepared by using a desired acid or base as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as
  • Suitable addition salts are formed from acids which form non-toxic salts and examples include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxyn
  • exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, ⁇ -hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene-1 -sulfonate and naphthalene-2-sulfonate.
  • an inventive basic compound is isolated as a salt
  • the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pK a than the free base form of the compound.
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • an inorganic or organic base such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia such as glycine and arginine
  • primary, secondary, and tertiary amines such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine
  • Certain of the compounds of this invention may form salts with 1-3 equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety).
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
  • Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
  • This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention, e.g., a hydrochloride salt, into another
  • a pharmaceutically acceptable salt of a compound of this invention e.g., a sulfate salt.
  • solvates of the compounds of Formula I, or salts thereof that are in crystalline form may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization.
  • Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as
  • Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.
  • the invention includes all such solvates.
  • the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
  • the compounds of this invention may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist.
  • the synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different R 1 and R 2 groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed.
  • the Schemes are shown with compounds only of Formula I, they are illustrative of processes that may be used to make the compounds of the invention.
  • Intermediates (compounds used in the preparation of the compounds of the invention) may also be present as salts.
  • the phrase "compound(s) of formula (number)" means a compound having that structural formula or a pharmaceutically acceptable salt thereof.
  • Specific compounds of this invention include the compounds of Examples 1 -2.
  • Representative compounds of this invention include:
  • ChemDraw 1 1.0 available from CambridgeSoft Corporation., 100 CambridgePark Drive, Cambridge, MA 02140, USA (http://www.cambridgesoft.com).
  • the compounds of Formula I can be prepared according to the methods outlined below.
  • Substitution of the 4-nitrogen of the 3,4-dihydroquinoxalin- 2(1 H)-one may be accomplished by treatment with an optionally substituted cyano- (hetero)aryl-carboxaldehyde. Conversion of the cyano moiety into a trifluoromethyl- oxadiazolyl group may be accomplished by treatment with hydroxylamine and
  • the invention also includes various deuterated forms of the compounds of Formula I.
  • Each available hydrogen atom attached to a carbon atom may be
  • deuterated alkyl groups e.g., /V-(deutero-methyl) amines
  • deuterated alkyl groups may be prepared by conventional techniques (see for example: methyl-c/3-amine available from Aldrich Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2).
  • Employing such compounds will allow for the preparation of compounds of Formula (I) in which various hydrogen atoms of the /V-methyl groups are replaced with a deuterium atom.
  • the present invention is directed to a method of inhibiting an HDAC which comprises contacting the acetylase with a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. More specifically, this invention is directed to a method of inhibiting HDAC comprising contacting a cell with an effective amount of a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of an HDAC-mediated disease or disorder comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof. As used herein, "patient” refers to a mammal, specifically, a human. A therapeutically "effective amount” is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
  • a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to inhibit the activity of HDAC such that a disease condition which is mediated by that activity is reduced, alleviated or prevented.
  • the amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC 50 ), efficacy (EC 5 o), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can
  • Treating is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by HDAC.
  • the methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
  • this invention is directed to a method of treating, ameliorating, or preventing an autoimmune disorder, an immunological disease, an inflammatory disorder, transplant/graft rejection (e.g., allograft), lymphopenia, or graft-versus-host disease (GvHD) in a patient, specifically in a human, comprising administering to the patient a compound of this invention, in an amount sufficient to increase the level and/or activity of a Treg cell or a population of Treg cells in the patient, thereby treating, ameliorating, or preventing the autoimmune disorder, inflammatory disorder,
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., allograft
  • GvHD graft-versus-host disease
  • transplant/graft rejection transplant/graft rejection, lymphopenia, or GvHD in the patient.
  • diseases and conditions that may be treated by the compounds of this invention include but not limited to type II diabetes mellitus, coronary artery disease, alopecia, allergies and allergic reactions, and sepsis/toxic shock.
  • Exemplary autoimmune disorders include, but are not limited to, multiple sclerosis, juvenile idiopathic arthritis, psoriatic arthritis, hepatitis C virus-associated mixed cryoglobulinemia, polymyositis, dermatomyositis, polyglandular syndrome type II, autoimmune liver disease, Kawasaki disease, myasthenia gravis, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX (syndrome)), type I diabetes, psoriasis, hypothyroidism, hemolytic anemia, autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED), thrombocytopenia, spondyloarthritis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, eczema, gastritis, or thyroiditis.
  • the inflammatory bowel disease IBD
  • autoimmune diseases include osteoarthritis, systemic sclerosis, sarcoidosis, insulin dependent diabetes mellitus (IDDM, type I diabetes), reactive arthritis, scleroderma, vasculitis, Wegener's granulomatosis, Hashimoto's disease, scleroderma, oophoritis, Lupus (SLE), Grave's disease, asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
  • IDDM insulin dependent diabetes mellitus
  • SLE oophoritis
  • Grave's disease asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • graft- versus-host disease e.g., graft- versus-host disease
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • graft- versus-host disease e.g., graft- versus-host disease
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • GvHD graft- versus-host disease
  • this invention is directed to a method of treating an HDAC-mediated neurodegenerative disease or disorder which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • This invention is also directed to a method of treatment of a neurodegenerative disease or disorder associated with deacetylases, such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • deacetylases such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA)
  • diseases and conditions include but are not limited to cystic fibrosis, osteoporosis, obesity, epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia, cardiac disease (e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation of infarct size in acute coronary syndrome), diseases or disorders involving muscular atrophy, gentamicin-induced hearing loss, drug resistance (e.g., drug resistance in osteosarcoma and colon cancer cells), infectious diseases, and immune deficiency/immunocompromised patients.
  • cystic fibrosis e.g., osteoporosis
  • obesity e.g., epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia
  • cardiac disease e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation
  • infectious diseases relate to various pathogen infections such as viral, fungal, bacterial, mycoplasm, and infections by unicellular and multicellular eukaryotic organisms.
  • Common human pathogens include but are not limited to HIV, HSV, HPV, Hepatitis A, B and C viruses, influenza, denge, zostrella, rubella, RSV, rotavirus, gram positive, gram negative, streptococcus, tetanus, staphalococcus, tuberculosis, listeria, and malaria.
  • the compounds of the invention may be employed alone or in combination with standard anti-cancer regimens for neoplastic cell, e.g., tumor cell and cancer cell, treatments.
  • this invention is directed to inhibitors of HDAC and their use to stop or reduce the growth of neoplastic cells, e.g., cancer cells and tumor cells.
  • neoplastic cells e.g., cancer cells and tumor cells.
  • carcinoma e.g., adenocarcinoma
  • heptaocellular carcinoma e.g., sarcoma
  • myeloma e.g., multiple myeloma
  • treating bone disease in multiple myeloma e.g., leukemia, childhood acute lymphoblastic leukemia and lymphoma (e.g., cutaneous cell lymphoma)
  • mixed types of cancers such as adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, and teratocarcinoma.
  • breast or prostate cancers or tumors are treated using the HDAC inhibitors of this invention.
  • Other cancers that may be treated using the compounds of this invention include, but are not limited to, bladder cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, endometrial cancer, pancreatic cancer, cervical cancer, ovarian cancer; head and neck cancer, and melanoma.
  • the present invention is further directed to a method of treating a B-cell lymphoma, particularly a B-cell lymphoma associated with deacetylases, which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • B-cell lymphomas associated with deacetylases include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and
  • this invention is directed to a method of treatment of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma
  • follicular lymphoma immunoblastic large cell lymphoma
  • precursor B-lymphoblastic lymphoma precursor B-lymphoblastic lymphoma
  • mantle cell lymphoma mantle cell lymphoma
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
  • Parenteral administration refers to routes of administration other than enteral,
  • transdermal, or by inhalation and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • Treatment of HDAC-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other agents, for example, in combination with 1-3 of the following agents: DNA methyltransferase inhibitors, acetyl transferase enhancers, proteasome or HSP90 inhibitors, and 1 -3 immunosuppressants that do not activate the T suppressor cells including but are not limited to corticosteroids, rapamycin, Azathioprine, Mycophenolate, Cyclosporine, Mercaptopurine (6-MP), basiliximab, daclizumab, sirolimus, tacrolimus, Muromonab-CD3, cyclophosphamide, and methotrexate, which are
  • the compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form.
  • a dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula I or a salt, particularly a pharmaceutically acceptable salt, thereof).
  • the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise 1 -3 additional pharmaceutically active compounds.
  • pharmaceutically-acceptable excipient means a material, composition or vehicle involved in giving form or consistency to the composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
  • the compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
  • Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants,
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • reaction was placed in a sealed vessel and heated to 150 °C for 15 m using microwave irradiation. After cooling, the reaction was diluted to 8 mL with MeOH, filtered, and purified directly via reverse phase prep-HPLC (10% - 100% MeCN in water with 0.05% TFA) to give the title compound (210 mg, 0.567 mmol, 59.0 % yield) as a yellow solid.
  • Tablets are prepared using conventional methods and are formulated as follows:
  • Capsules are prepared using conventional methods and are formulated as follows:
  • HDAC9 Histone Deacetylase 9
  • Novel histone deacetylase 9 (HDAC9) inhibitors were characterized in an in vitro biochemical functional assay.
  • the assay measures the increased fluorescent signal due to deacetylation, by HDAC9, of a fluorogenic substrate.
  • the commercial available substrate is Class lla HDAC-specific and contains an acetylated lysine residue and would releases the fluorescent signal upon trypsin cleavage after deacetylation.
  • test compounds diluted to various concentrations in 100% DMSO are first dispensed into 384-well assay plates.
  • Recombinant HDAC9 isoform 4 (purchased from BPS Bioscience) in complete assay buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1 mM MgCI 2 , 0.05% BSA & 0.005% Tween 20) were then added to each well (5uL/well) using Multidrop Combi (Thermo Scientific), followed by 5 uL/well substrate (purchased from BPS Bioscience, 4.5 uM final).
  • plC 50 s For concentration/dose response experiments, normalized data were fit and plC 50 s determined using conventional techniques. The plC 50 s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compounds of Examples 1-2 exhibited a plC 50 between 5.0 and 9.0 e.g., for example, the compound of Example 2 inhibited HDAC9 in the above method with a mean plC 50 > 6.
  • HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival L. Wang, et al., Am. J. Transplant 9, S621 (2009).
  • HDAC-MEF2 complexes A. Nebbioso, F. Manzo, M. Miceli, M. Conte, L. Manente, A. Baldi, A. De Luca, D. Rotili, S. Valente, A. Mai, A. Usiello, H. Gronemeyer, L. Altucci, EMBO reports 10 (7) , 776-782, 2009. and references therein.

Abstract

La présente invention concerne des composés qui inhibent les enzymes histone désacétylases (HDAC), la préparation de ces composés ou sels desdits composés, l'utilisation de ces composés dans le traitement de maladies neurodégénératives ou d'états neurodégénératifs améliorés par l'inhibition de l'activité HDAC. L'invention concerne également des compositions pharmaceutiques qui comprennent ces composés.
PCT/US2012/062513 2011-10-31 2012-10-30 Composés et procédés WO2013066838A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161553308P 2011-10-31 2011-10-31
US61/553,308 2011-10-31
US201261596274P 2012-02-08 2012-02-08
US61/596,274 2012-02-08

Publications (1)

Publication Number Publication Date
WO2013066838A1 true WO2013066838A1 (fr) 2013-05-10

Family

ID=48192668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/062513 WO2013066838A1 (fr) 2011-10-31 2012-10-30 Composés et procédés

Country Status (1)

Country Link
WO (1) WO2013066838A1 (fr)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014321A1 (fr) 2015-07-17 2017-01-26 Takeda Pharmaceutical Company Limited Dérivés oxadiazole utiles en tant qu'inhibiteurs de hdac
WO2017014170A1 (fr) * 2015-07-17 2017-01-26 武田薬品工業株式会社 Composé hétérocyclique
KR20170013186A (ko) 2015-07-27 2017-02-06 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170013187A (ko) 2015-07-27 2017-02-06 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170013836A (ko) 2015-07-27 2017-02-07 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설폰아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170017792A (ko) 2015-08-04 2017-02-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2017055473A1 (fr) 2015-10-02 2017-04-06 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017072247A1 (fr) 2015-10-28 2017-05-04 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017093348A1 (fr) 2015-12-02 2017-06-08 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017162868A1 (fr) 2016-03-24 2017-09-28 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017178549A1 (fr) 2016-04-12 2017-10-19 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017220485A1 (fr) 2016-06-21 2017-12-28 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018015458A1 (fr) 2016-07-22 2018-01-25 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018015449A1 (fr) 2016-07-22 2018-01-25 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018029242A1 (fr) 2016-08-11 2018-02-15 Syngenta Participations Ag Dérivés d'oxadiazole microbicides
WO2018055135A1 (fr) 2016-09-23 2018-03-29 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018065414A1 (fr) 2016-10-06 2018-04-12 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018158365A1 (fr) 2017-03-03 2018-09-07 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018162643A1 (fr) 2017-03-10 2018-09-13 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018177894A1 (fr) 2017-03-31 2018-10-04 Syngenta Participations Ag Compositions fongicides
WO2018177880A1 (fr) 2017-03-31 2018-10-04 Syngenta Participations Ag Compositions fongicides
WO2018184988A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184985A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184987A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184984A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018185013A1 (fr) 2017-04-03 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184986A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018185211A1 (fr) 2017-04-06 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018187553A1 (fr) * 2017-04-06 2018-10-11 Fmc Corporation Oxadiazoles à activité fongicide
WO2018184982A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018219773A1 (fr) 2017-06-02 2018-12-06 Syngenta Participations Ag Compositions fongicides
WO2018219825A1 (fr) 2017-06-02 2018-12-06 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US20180368409A1 (en) * 2015-11-19 2018-12-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2019002151A1 (fr) 2017-06-28 2019-01-03 Syngenta Participations Ag Compositions fongicides
WO2019012011A1 (fr) 2017-07-12 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011929A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011923A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011928A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019012001A1 (fr) 2017-07-12 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011926A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019012003A1 (fr) 2017-07-13 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019020501A1 (fr) 2017-07-28 2019-01-31 Basf Se Préparation de 3-aryl-5-trifluorométhyl-1,2,4-oxadiazoles substitués
WO2019097054A1 (fr) 2017-11-20 2019-05-23 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
WO2019207062A1 (fr) 2018-04-26 2019-10-31 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2020002331A1 (fr) 2018-06-29 2020-01-02 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
WO2020007658A1 (fr) 2018-07-02 2020-01-09 Syngenta Crop Protection Ag Dérivés de 3-(2-thiényl)-5-(trifluorométhyl) -1,2,4-oxadiazole en tant que fongicides agrochimiques
WO2020016180A1 (fr) 2018-07-16 2020-01-23 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
WO2020078732A1 (fr) 2018-10-17 2020-04-23 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
WO2020212513A1 (fr) 2019-04-18 2020-10-22 Syngenta Crop Protection Ag Procédé de préparation de dérivés d'oxadiazole microbiocides
WO2020240493A1 (fr) 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. Composés dérivés de 1,3,4-oxadiazole homophtalimide utilisés comme inhibiteur de l'histone désacétylase 6, et composition pharmaceutique les comprenant
WO2022013728A1 (fr) * 2020-07-14 2022-01-20 Chong Kun Dang Pharmaceutical Corp. Nouveaux composés utilisés en tant qu'inhibiteurs de l'histone désacétylase 6 et composition pharmaceutique les comprenant
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
RU2817736C1 (ru) * 2020-07-14 2024-04-19 Чонг Кун Данг Фармасьютикал Корп. Новые соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194797A1 (en) * 2003-09-01 2006-08-31 Jun Takeuchi Condensed ring compound and use thereof
WO2010031577A1 (fr) * 2008-09-18 2010-03-25 Jerini Ag Utilisation d'antagonistes du récepteur de la bradykinine b1 dans un traitement de fibrose intestinale
US20110046159A1 (en) * 2008-04-29 2011-02-24 Merck Patent Gesellschaft Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194797A1 (en) * 2003-09-01 2006-08-31 Jun Takeuchi Condensed ring compound and use thereof
US20110046159A1 (en) * 2008-04-29 2011-02-24 Merck Patent Gesellschaft Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
WO2010031577A1 (fr) * 2008-09-18 2010-03-25 Jerini Ag Utilisation d'antagonistes du récepteur de la bradykinine b1 dans un traitement de fibrose intestinale

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017014321A1 (fr) 2015-07-17 2017-01-26 Takeda Pharmaceutical Company Limited Dérivés oxadiazole utiles en tant qu'inhibiteurs de hdac
WO2017014170A1 (fr) * 2015-07-17 2017-01-26 武田薬品工業株式会社 Composé hétérocyclique
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10308643B2 (en) 2015-07-17 2019-06-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20170013186A (ko) 2015-07-27 2017-02-06 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170013187A (ko) 2015-07-27 2017-02-06 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170013836A (ko) 2015-07-27 2017-02-07 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설폰아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20170017792A (ko) 2015-08-04 2017-02-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017055473A1 (fr) 2015-10-02 2017-04-06 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017072247A1 (fr) 2015-10-28 2017-05-04 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US20180368409A1 (en) * 2015-11-19 2018-12-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10674727B2 (en) * 2015-11-19 2020-06-09 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017093348A1 (fr) 2015-12-02 2017-06-08 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017162868A1 (fr) 2016-03-24 2017-09-28 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017178549A1 (fr) 2016-04-12 2017-10-19 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2017220485A1 (fr) 2016-06-21 2017-12-28 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018015458A1 (fr) 2016-07-22 2018-01-25 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018015449A1 (fr) 2016-07-22 2018-01-25 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018029242A1 (fr) 2016-08-11 2018-02-15 Syngenta Participations Ag Dérivés d'oxadiazole microbicides
WO2018055135A1 (fr) 2016-09-23 2018-03-29 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018065414A1 (fr) 2016-10-06 2018-04-12 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018158365A1 (fr) 2017-03-03 2018-09-07 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018162643A1 (fr) 2017-03-10 2018-09-13 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
WO2018177880A1 (fr) 2017-03-31 2018-10-04 Syngenta Participations Ag Compositions fongicides
WO2018177894A1 (fr) 2017-03-31 2018-10-04 Syngenta Participations Ag Compositions fongicides
WO2018185013A1 (fr) 2017-04-03 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184987A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184986A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184988A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184985A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184984A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018184982A1 (fr) 2017-04-05 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
AU2018249537B2 (en) * 2017-04-06 2022-03-31 Fmc Corporation Fungicidal oxadiazoles
CN110650956A (zh) * 2017-04-06 2020-01-03 Fmc公司 杀真菌噁二唑
WO2018185211A1 (fr) 2017-04-06 2018-10-11 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
US11708358B2 (en) 2017-04-06 2023-07-25 Fmc Corporation Fungicidal oxadiazoles
IL269786B2 (en) * 2017-04-06 2023-07-01 Fmc Corp Fungal oxidases
JP7235672B2 (ja) 2017-04-06 2023-03-08 エフ エム シー コーポレーション 殺真菌性オキサジアゾール
IL269786B1 (en) * 2017-04-06 2023-03-01 Fmc Corp Fungal oxidases
JP2020516598A (ja) * 2017-04-06 2020-06-11 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 殺真菌性オキサジアゾール
EP3957636A1 (fr) * 2017-04-06 2022-02-23 FMC Corporation Oxadiazoles fongicides
WO2018187553A1 (fr) * 2017-04-06 2018-10-11 Fmc Corporation Oxadiazoles à activité fongicide
CN110650956B (zh) * 2017-04-06 2024-03-08 Fmc公司 杀真菌噁二唑
WO2018219825A1 (fr) 2017-06-02 2018-12-06 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2018219773A1 (fr) 2017-06-02 2018-12-06 Syngenta Participations Ag Compositions fongicides
WO2019002151A1 (fr) 2017-06-28 2019-01-03 Syngenta Participations Ag Compositions fongicides
WO2019011923A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011929A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011928A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019011926A1 (fr) 2017-07-11 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019012011A1 (fr) 2017-07-12 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019012001A1 (fr) 2017-07-12 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019012003A1 (fr) 2017-07-13 2019-01-17 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
CN110997644B (zh) * 2017-07-28 2023-12-12 巴斯夫欧洲公司 取代的3-芳基-5-三氟甲基-1,2,4-噁二唑类的制备
WO2019020501A1 (fr) 2017-07-28 2019-01-31 Basf Se Préparation de 3-aryl-5-trifluorométhyl-1,2,4-oxadiazoles substitués
CN110959005B (zh) * 2017-07-28 2024-01-19 巴斯夫欧洲公司 取代的3-芳基-5-三氟甲基-1,2,4-噁二唑类的制备
CN110959005A (zh) * 2017-07-28 2020-04-03 巴斯夫欧洲公司 取代的3-芳基-5-三氟甲基-1,2,4-噁二唑类的制备
CN110997644A (zh) * 2017-07-28 2020-04-10 巴斯夫欧洲公司 取代的3-芳基-5-三氟甲基-1,2,4-噁二唑类的制备
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
WO2019097054A1 (fr) 2017-11-20 2019-05-23 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2019207062A1 (fr) 2018-04-26 2019-10-31 Syngenta Participations Ag Dérivés d'oxadiazole microbiocides
WO2020002331A1 (fr) 2018-06-29 2020-01-02 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
WO2020007658A1 (fr) 2018-07-02 2020-01-09 Syngenta Crop Protection Ag Dérivés de 3-(2-thiényl)-5-(trifluorométhyl) -1,2,4-oxadiazole en tant que fongicides agrochimiques
WO2020016180A1 (fr) 2018-07-16 2020-01-23 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2020078732A1 (fr) 2018-10-17 2020-04-23 Syngenta Crop Protection Ag Dérivés d'oxadiazole microbiocides
WO2020212513A1 (fr) 2019-04-18 2020-10-22 Syngenta Crop Protection Ag Procédé de préparation de dérivés d'oxadiazole microbiocides
WO2020240493A1 (fr) 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. Composés dérivés de 1,3,4-oxadiazole homophtalimide utilisés comme inhibiteur de l'histone désacétylase 6, et composition pharmaceutique les comprenant
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11958845B2 (en) 2019-09-27 2024-04-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2022013728A1 (fr) * 2020-07-14 2022-01-20 Chong Kun Dang Pharmaceutical Corp. Nouveaux composés utilisés en tant qu'inhibiteurs de l'histone désacétylase 6 et composition pharmaceutique les comprenant
RU2817736C1 (ru) * 2020-07-14 2024-04-19 Чонг Кун Данг Фармасьютикал Корп. Новые соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их

Similar Documents

Publication Publication Date Title
WO2013066838A1 (fr) Composés et procédés
WO2013066839A2 (fr) Composés et procédés
WO2013066835A2 (fr) Composés et procédés
WO2013006408A1 (fr) Composés et procédés
WO2013066831A1 (fr) Composés et procédés
US8981084B2 (en) Oxadiazole HDAC inhibitors
AU2011205283B2 (en) Compounds and methods
WO2013066833A1 (fr) Composés et procédés pour inhiber les enzymes histone désacétylases (hdac)
US20180085365A1 (en) Amino-quinolines as kinase inhibitors
JP6846574B2 (ja) スルホンアミド化合物およびその使用
EP2523560A1 (fr) Composés et procédés
KR20230049584A (ko) 아미노산 화합물을 사용한 호흡기 질환의 치료
EP2566477A1 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
US20160207913A1 (en) Prodrugs of amino quinazoline kinase inhibitor
EP4061364A1 (fr) Composés hétéroaryles
JPWO2019107386A1 (ja) 抗腫瘍剤
KR20140117651A (ko) 이소퀴놀린 및 나프티리딘 유도체
JP2019501896A (ja) 抗菌化合物としての置換ベンザジノン
WO2013066836A1 (fr) Composés et procédés
WO2013066834A1 (fr) Composés et procédés
WO2013066832A1 (fr) Composés et procédés
CN103373997A (zh) 含有锌结合基的吡啶并萘啶类HDAC和mTOR抑制剂
WO2014159938A1 (fr) Aminothiazoles substitués pour le traitement de la tuberculose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12845757

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/09/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12845757

Country of ref document: EP

Kind code of ref document: A1